-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Fxj0WqpXDDJoTsf/E22KRmNB5HnRiy0LW6t1CciRIHV//oAnvEFW8ACSBRJaW68A D3EpeMm28v5TeT24rtmcPg== 0001181431-08-024625.txt : 20080410 0001181431-08-024625.hdr.sgml : 20080410 20080410162420 ACCESSION NUMBER: 0001181431-08-024625 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20080404 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20080410 DATE AS OF CHANGE: 20080410 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LEMAITRE VASCULAR INC CENTRAL INDEX KEY: 0001158895 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33092 FILM NUMBER: 08750220 BUSINESS ADDRESS: STREET 1: 63 2ND AVE CITY: BURLINGTON STATE: MA ZIP: 01803 BUSINESS PHONE: 781-221-2266 MAIL ADDRESS: STREET 1: 63 2ND AVE CITY: BURLINGTON STATE: MA ZIP: 01803 8-K 1 rrd202737.htm LEMAITRE 8-K 08-04-04 Prepared By R.R. Donnelley Financial -- Form 8-K
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 8-K
 
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  04/04/2008
 
LeMaitre Vascular, Inc.
(Exact name of registrant as specified in its charter)
 
Commission File Number:  001-33092
 
Delaware
  
04-2825458
(State or other jurisdiction of
  
(IRS Employer
incorporation)
  
Identification No.)
 
63 Second Avenue
Burlington, MA 01803
(Address of principal executive offices, including zip code)
 
781-221-2266
(Registrant’s telephone number, including area code)
 
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
Item 1.01.    Entry into a Material Definitive Agreement
 
On April 7, 2008, LeMaitre Vascular, Inc. (the "Company") and Rodger P. Nordblom and Peter C. Nordblom, as Trustees of Northwest Associates ("Landlord"), entered into a Third Amendment of Lease dated as of February 26, 2008 (the "Amendment"). The Amendment amends the Lease between the Company and Landlord dated as of March 31, 2003, that was filed as Exhibit 10.1 to the Company's Form S-1 Registration Statement filed with the Securites and Exchange Commission on April 25, 2006, as that Lease has been amended to date.

The Amendment extends the term of the Company's lease of its corporate headquarters in Burlington, Massachusetts, by six months (i.e., through September 30, 2009), at the same Annual Fixed Rent Rate as currently in effect. A copy of the Amendment is set forth as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

 
 
Item 5.02.    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
 
On April 4, 2008, Kevin D. Kelly resigned from his position as the Company's Senior Vice President, North American Sales, in order to pursue other business opportunities.

On April 10, 2008, the Company named Robert V. Linden to replace Mr. Kelly in the capacity of Vice President, North American Sales. Mr. Linden has been a member of the Company's sales force since 2002, most recently serving as the Company's Director of Sales for the Eastern United States and Canada.

 
 
Item 7.01.    Regulation FD Disclosure
 
On April 10, 2008, the Company issued a press release announcing that Kevin D. Kelly, Senior Vice President, North American Sales, has departed the Company to pursue other interests, and that Robert V. Linden has been named Vice President, North American Sales, effective immediately. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.

The information set forth in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

 
 
Item 9.01.    Financial Statements and Exhibits
 
The following exhibits are furnished as part of this report, where indicated:

(d) Exhibits.

Exhibit No.    Description

10.1                Third Amendment of Lease

99.1                Press release issued by LeMaitre Vascular, Inc. on April 10, 2008, furnished herewith.
 

 

Signature(s)
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
 
LeMaitre Vascular, Inc.
 
 
Date: April 10, 2008
     
By:
 
/s/    Christopher H. Martin

               
Christopher H. Martin
               
Assistant Secretary
 
 


 

Exhibit Index
 
Exhibit No.

  
Description

EX-10.1
  
Third Amendment of Lease
EX-99.1
  
Press release issued by LeMaitre Vascular, Inc. on April 10, 2008, furnished herewith.
EX-10.1 2 rrd202737_23948.htm THIRD AMENDMENT OF LEASE THIRD AMENDMENT OF LEASE

THIRD AMENDMENT OF LEASE

THIS AMENDMENT made and entered into as of the 26th day of February, 2008 by and between Rodger P. Nordblom and Peter C. Nordblom, as Trustees of Northwest Associates ("Landlord") and LeMaitre Vascular, Inc. ("Tenant").

WITNESSETH

WHEREAS, Landlord and Tenant entered into a lease dated March 31, 2003, as amended by the First Amendment of Lease dated May 21, 2004 and by the Second Amendment of Lease dated May 21, 2007 (collectively the "Lease") for the Premises containing 27,098 rentable square feet in the building located at 63 Second Avenue, Burlington, Massachusetts; and

WHEREAS, Landlord and Tenant would like to extend the term of the Lease for an additional six (6) Months expiring on September 30, 2009;

NOW THEREFORE, in consideration of the mutual agreements contained herein, the parties agree that the Lease shall be amended as follows, effective as of the date of this Amendment:

1. The Expiration Date as contained in Section 1.1 of the Lease, shall be changed to September 30, 2009.

2. The Annual Fixed Rent Rate and the Monthly Fixed Rent Rate specified in Section 1.1 of the Lease shall remain at $342,672 and $28,556.00 respectively through September 30, 2009.

3. Capitalized terms used herein without definition shall have the meanings ascribed to them in the Lease.

As amended hereby, the Lease is ratified and confirmed in all respects, and shall continue in full force and effect.

 

 

The remainder of this page has been intentionally left blank

 

 

 

IN WITNESS WHEREOF, the parties have executed this Third Amendment of Lease under seal as of the date first written above.

LANDLORD:

 

 

/s/ Peter C. Nordblom

As Trustee and not individually

 

/s/ Rodger P. Nordblom

As Trustee and not individually

 

TENANT:

LEMAITRE VASCULAR, INC.

 

By: /s/ Trent G. Kamke

Print Name: Trent G. Kamke

Print Title: Senior VP-Operations

Hereunto duly authorized

EX-99.1 3 rrd202737_23953.htm PRESS RELEASE ISSUED BY LEMAITRE VASCULAR, INC. ON APRIL 10, 2008, FURNISHED HEREWITH. LEMAITRE VASCULAR RECEIVES CONDITIONAL IDE APPROVAL TO BEGIN ENDOFIT AORTO-UNI-ILIAC STENT GRAFT PIVOTAL STUDY

LEMAITRE VASCULAR ANNOUNCES CHANGES TO ITS EXECUTIVE MANAGEMENT TEAM

 

Burlington, MA -- 04/10/2008 -- LeMaitre Vascular, Inc. (NASDAQ: LMAT - News) today announced the departure of Kevin D. Kelly, Senior Vice President, North American Sales, to pursue other business opportunities and the appointment of Robert V. Linden to Vice President, North American Sales.

Mr. Linden has approximately six years North American sales experience with LeMaitre Vascular. He joined LeMaitre Vascular in July 2002 as a Sales Representative and has served in positions of increasing responsibility within the North American organization. Since January 2008, he has served as Director of Sales for the Eastern United States and Canada, supervising three of the company's five North American sales regions. From 2005 through 2007, Mr. Linden served as Regional Sales Manager. Prior to LeMaitre Vascular, Mr. Linden served as a sales representative at several medical device companies, including Vasca, Inc., Atrium Medical Corporation, Active Medical, Inc., and DePuy Orthopedics, Inc. Mr. Linden holds a B.A. in Marketing from The Pennsylvania State University.

LeMaitre Vascular Chairman and Chief Executive Officer George W. LeMaitre stated, "We want to thank Kevin Kelly for his contributions and we wish him the best. We are thrilled to promote Rob Linden to the position of Vice President, North American Sales. I have watched Rob succeed at our company in positions of increasing responsibility over the past six years. We believe he will build on this experience to provide effective leadership for our North American sales organization."

About LeMaitre Vascular

LeMaitre Vascular develops, manufactures, and markets medical devices for the treatment of peripheral vascular disease. The company's principal executive offices are located at 63 Second Avenue, Burlington, Massachusetts 01803.

Certain statements set forth above that are not clearly historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge, these forward-looking statements are neither promises nor guarantees. The forward-looking statements made in this release are made only as of the date hereof, and the company disclaims any intention or responsibility for updating predictions or expectations contained in this release.

CONTACT:
Aaron Grossman
Office: 781.221.2266
Investor Relations
LeMaitre Vascular, Inc.

SOURCE:
LeMaitre Vascular, Inc.

-----END PRIVACY-ENHANCED MESSAGE-----